Cefpodoxime Chemical Properties

Melting point:

200-202°C

Density 

1.78±0.1 g/cm3(Predicted)

RTECS 

XI0367365

storage temp. 

Sealed in dry,Store in freezer, under -20°C

solubility 

Soluble in DMSO

pka

2.77±0.50(Predicted)

form 

Solid

color 

White to off-white

Sensitive 

Light Sensitive

BRN 

6021381

Stability:

Hygroscopic

Safety Information

Hazard Codes 

Xn

Risk Statements 

42/43

Safety Statements 

22-36/37-45

WGK Germany 

3

Cefpodoxime Usage And Synthesis

Chemical Properties

Off-White Solid

Uses

A metabolite of Cefpodoxime Proxetil. An antibacterial.

Uses

Cefpodoxime Proxetil metabolite antibiotic

Uses

A metabolite of Cefpodoxime Proxetil (C243860). An antibacterial.

Definition

ChEBI: A third-generation cephalosporin antibiotic with methoxymethyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamino substituents at positions 3 and 7, respectively, of the cephem skeleton. Given by mouth as its proxetil ester prodrug, it is used to treat acute otitis media, pharyngitis, and sinusitis.

brand name

Vantin (Pharmacia & Upjohn).

Antimicrobial activity

It is stable to a wide range of plasmid-mediated β-lactamases. It induces the chromosomal β-lactamases of Ps. aeruginosa, Enterobacter spp., S. marcescens and Citrobacter spp., but is a less potent inducer than cefoxitin.

Biological Activity

cefpodoxime, as known as r 3763, is a metabolite of cefpodoxime proxetil. it is demonstrated that cefpodoxime, as an oral third generation cephalosporin antibiotic, is active against most gram-positive and gram-negative bacteria.cefpodoxime suppresses bacterial septum and cell wall synthesis by binding to penicillin-binding proteins (pbps) located in the bacterial cytoplasmic membrane.

Pharmacokinetics

Oral absorption: c. 50%
C_max 200 mg oral: 2.1 mg/L after 3 h
Plasma half-life: c. 2.2 h
Volume of distribution: c. 35 L
Plasma protein binding: 20–30%
Absorption and distribution
The ester is rapidly hydrolyzed to the parent compound in the small intestine. Bioavailability increases to 65% if taken with food, but antacids and H2-receptor antagonists reduce absorption. Unabsorbed drug is hydrolyzed and excreted in the feces.
It is well distributed and penetrates well into tissues (including lung tissue) and inflammatory exudate to achieve concentrations inhibitory to common pathogens.
Metabolism and excretion
The hydrolyzed prodrug is not subject to further metabolism. About 80% of the absorbed compound (30–40% of the original dose) appears in the urine over 24 h. Excretion is by glomerular filtration and tubular secretion; probenecid delays secretion and increases the peak plasma concentration.
Metabolism and excretion
The hydrolyzed prodrug is not subject to further metabolism. About 80% of the absorbed compound (30–40% of the original dose) appears in the urine over 24 h. Excretion is by glomerular filtration and tubular secretion; probenecid delays secretion and increases the peak plasma concentration.

Clinical Use

Cefpodoxime has been used principally for the treatment of upper and lower respiratory tract infections in children and adults.

Side effects

The drug is well tolerated, but gastrointestinal disturbance with diarrhea is common. Pseudomembranous colitis has been reported occasionally. Other side effects are those common to cephalosporins.

in vitro

cefpodoxime showed antibacterial activities against obligatory anaerobes and salmonella spp., shigella spp. and neisseria meningitides. the activity of cefpodoxime was less active than r95867, an active form of cs-834, against gram-negative bacteria [1]. cefpodoxime was quite stable to hydrolysis by β-lactamases produced from b. cereus and e. coli hb101/pbr322 [2].

in vivo

male ddy mice were administered orally in a volume of 0.2 ml of 0.5% carboxymethyl cellulose sodium salt. after 7 days, it was shown that cefpodoxime had good efficacy against streptococcus spp. and k. pneumoniae infection in mice [1].

References

[1]. sakagawa, e., otsuki, m., oh, t., & nishino, t. in-vitro and in-vivo antibacterial activities of cs-834, a new oral carbapenem. journal of antimicrobial chemotherapy, 1998; 42: 426-437.
[2]. fukuoka, t., ohya, s., utsui, y., domon, h., takenouchi, t., koga, t., … kuwahara, s. in vitro and in vivo antibacterial activities of cs-834, a novel oral carbapenem. antimicrobial agents and chemotherapy, 1997; 41(12): 2652–2663.

Cefpodoxime(80210-62-4)Related Product Information

• MTT
• 2-Methyl-4-isothiazolin-3-one
• Fosthiazate
• Benzothiazole
• 2,2'-Dithiobis(benzothiazole)
• Methylchloroisothiazolinone/methylisothiazolinone mixture (MCIT/MIT)
• 1-CHLOROETHYL ISOPROPYL CARBONATE (JCC-1)(INTERMEDIATE OF CEFPODOXIME PROXETIL (BANAN)),1-chloroethyl isopropyl carbonate (intermediate of cefpodoxime proxetil)
• Cefotaxime sodium
• Cefotaxime
• Cefpodoxime Proxetil JPFa,CEFPODOXIME PROXETIL,Cefpodoxime-d3, Free Acid
• Cefpodoxime
• Ceftioxide
• CEFPODOXIME SODIUM
• Cefpodoxime acid
• CEFPODOXIME, FREE ACID
• Cefpodoxime Sodium Sterile